Hutchison China Meditech Limited Director's Share Dealing (6317G)
August 09 2016 - 3:07AM
UK Regulatory
TIDMHCM
RNS Number : 6317G
Hutchison China Meditech Limited
09 August 2016
Director's Share Dealing
London: Tuesday, August 9, 2016: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification
that the spouse of Mr Christopher Nash, Independent Non-executive
Director, has purchased 3,120 and 42 ordinary shares of US$1.00
each in Chi-Med (the "Ordinary Shares") at a price of GBP19.00 and
GBP18.99 per share respectively on August 4, 2016.
Following the above transaction, the combined holding of Mr Nash
and his spouse is 39,596 Ordinary Shares, representing
approximately 0.065% of the current issued share capital of
Chi-Med.
The notification set out below is provided in accordance with
the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated
---- ----------------------------------------------------------------------------------------------------------------
a) Name Ms Rebecca Pynt
---- ------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------------------------------------
a) Position/status Spouse of Mr Christopher Nash, an Independent
Non-executive Director of Chi-Med
---- ------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial notification
---- ------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- ----------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
---- ------------------------------------------------------- -------------------------------------------------------
b) LEI N/A
---- ------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Ordinary Shares of US$1.00 each
instrument DI ISIN: KYG4672N1016
Identification code ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Acquisition of 3,120 and 42 Ordinary Shares on August
4, 2016 at a price of GBP19.00 and GBP18.99
respectively
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
GBP19.00 3,120
---------- ----------
GBP18.99 42
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2016-08-04
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction London Stock Exchange (XLON)
---- ------------------------------------------------------- -------------------------------------------------------
NOTES TO EDITORS
About Chi-Med
Chi-Med is an innovative China-based biopharmaceutical company
which researches, develops, manufactures and sells pharmaceuticals
and healthcare products. Its Innovation Platform, Hutchison
MediPharma Limited, focuses on discovering and developing
innovative therapeutics in oncology and autoimmune diseases for the
global market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Contacts
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media Enquiries
Anthony Carlisle, +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
Citigate Dewe Rogerson
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Brian Korb, The Trout Group +1 (917) 653 5122 (Mobile) bkorb@troutgroup.com
David Dible, +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Citigate Dewe Rogerson
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLIFIDTRIAIIR
(END) Dow Jones Newswires
August 09, 2016 03:07 ET (07:07 GMT)